Sangamo Surges to 13-Year High on HIV Therapy Results
This article is for subscribers only.
Sangamo BioSciences Inc., a drug developer focused on gene editing, rose to its highest value in 13 years on studies showing its treatment may help patients control HIV without daily therapy, potentially curing them.
Sangamo jumped 17 percent to $22.96 at the close in New York, its highest price since Jan. 31, 2001. The shares of the Richmond, California-based company have more than doubled in the last year.